For the first time, WHO’s treatment guidelines consist of a clear advice for using prolonged-acting injectable cabotegravir and rilpivirine (CAB/RPV) in its place switching option for antiretroviral therapy (Artwork) for Grown ups and adolescents that have reached complete viral suppression on oral Artwork and would not have active hepatitis B https://goo.gl/maps/kyMiFZydmjf97mh8A